Physician profile
Jerald M Mefferd
NPI 1356737985
$1,885.62
in general payments reported to CMS, 2019-2025
16 companies · $118 in 2025
The $118 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $604 · 2021: $565 · 2022: $185 · 2023: $79.01 · 2024: $334 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $775.67 | 2020-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $355.84 | 2020-2024 | |
| Corium, LLC | $237.31 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $159.72 | 2024 | Qelbree |
| Cranial Technologies, INC | $78.64 | 2020-2022 | |
| Aytu Biopharma, INC. | $47.66 | 2020-2021 | |
| Adlon Therapeutics L.P. | $43.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.07 | 2021-2022 | |
| Pfizer INC. | $32.58 | 2024-2025 | |
| Genentech USA, INC. | $30.65 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $18.91 | 2023 | Daybue |
| Neos Therapeutics, LP | $18.48 | 2022 | |
| Sanofi Pasteur INC. | $16.07 | 2023 | |
| Phadia US INC. | $15.70 | 2020 | |
| Collegium Pharmaceutical, INC. | $13.61 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $2.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Mefferd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.